BriaCell Announces Closing of US$25 Million Public Offering

BERKELEY, Calif. and VANCOUVER, British Columbia, February 26, 2021— BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today closed its previously announced underwritten public offering in the United States. The Company offered 4,852,353 common units at a public offering price …

BriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing

BERKELEY, Calif. and VANCOUVER, British Columbia, February 23, 2021— BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced the pricing of an underwritten public offering in the United States of 5,882,353 units, each unit consisting of one share of …

BriaCell Presents Clinical Data at 2021 Keystone Symposium

Clinical and pathological findings presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: • Median overall survival of 12.5 months in patients with moderately-well differentiated tumors despite an average of 7 failed prior therapy regimens (versus 7.2-9.8 months of others). • Prolonged survival rates and …

BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies

• Clinical and pathological data from clinical trial of the Bria-IMT™ regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the Keystone Symposia, Jan. 25-27, 2021. BERKELEY, Calif. and VANCOUVER, British Columbia, January 12, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), …

BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®

Disease control and survival data is presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: • Maximum tumor reduction and clinical benefit was observed in heavily pre-treated advanced breast cancer patients, particularly with moderately-well differentiated tumors. • Patients with moderately-well differentiated tumors had a higher …

BriaCell Appoints Martin Schmieg to Board of Directors

BERKELEY, Calif., and VANCOUVER, British Columbia, Dec. 1, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously …

BRIACELL THERAPEUTICS CORP. CLOSES DEBT FINANCING

BERKELEY, Calif., and VANCOUVER, British Columbia, November 17, 2020 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has closed a brokered private placement (the “Offering”) of an unsecured convertible debenture unit of the Company (the …

BriaCell Announces Collaboration with the National Cancer Institute

• BriaCell and National Cancer Institute to collaborate on Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy, as a treatment for cancer. BERKELEY, Calif., and VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to …

BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months

• Overall Survival of 13.3 months in patients, including 14 months in patients with Grade I/II tumors, suggesting clinical benefit; • Comparison: 7.2-9.8 months in similar patients with metastatic breast cancer in the third line setting without BriaCell’s treatment; • Additional overall survival data will be presented at the 2020 San Antonio Breast Cancer Symposium®, …

BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11

• Clinical and pathological findings to be presented from clinical trial of the Bria-IMT™ regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer. BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted …